Petros Pharmaceuticals, Inc. (PTPI) Analyst Estimates Annual - Discounting Cash Flows
PTPI
Petros Pharmaceuticals, Inc.
PTPI (NASDAQ)
Period Ending: 2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
Number of Analysts 1 1 1 1 1 1
Estimated Revenue
Low 27.78 20.62 11.03 5.47 5.43 7.7
Average 27.78 20.62 11.03 5.47 5.43 7.7
High 27.78 20.62 11.03 5.47 5.43 7.7
Estimated EBITDA
Low -21.85 -16.22 -8.67 -4.31 -4.27 -6.06
Average -21.85 -16.22 -8.67 -4.31 -4.27 -6.06
High -21.85 -16.22 -8.67 -4.31 -4.27 -6.06
Estimated EBIT
Low -27.78 -20.62 -11.03 -5.47 -5.43 -7.7
Average -27.78 -20.62 -11.03 -5.47 -5.43 -7.7
High -27.78 -20.62 -11.03 -5.47 -5.43 -7.7
Estimated Net Income
Low 2.73 -140.5 -220.7 -218.7 -427.4 -1,033
Average 2.73 -140.5 -220.7 -218.7 -427.4 -1,033
High 2.73 -140.5 -220.7 -218.7 -427.4 -1,033
Estimated SGA Expenses
Low 49.88 37.02 19.79 9.83 9.75 13.83
Average 49.88 37.02 19.79 9.83 9.75 13.83
High 49.88 37.02 19.79 9.83 9.75 13.83
Estimated EPS
Low 0.34 -17.5 -27.5 -27.25 -53.25 -128.8
Average 0.34 -17.5 -27.5 -27.25 -53.25 -128.8
High 0.34 -17.5 -27.5 -27.25 -53.25 -128.8
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program